Medical misinformation, life sciences burnout, and AI-powered content creation collide in this episode with Dr. Ome Ogbru, founder & CEO of AINGENS and creator of MACg (Medical Affairs Content Generator). Learn how AI in biotech is tackling the complexities of medical affairs—from literature review and content automation to compliance and regulatory writing. ⚡️ WHAT YOU’LL LEARN: - Why medical affairs and regulatory teams can’t rely on ChatGPT alone. - How MACg integrates real‑t...
What happens when 3,500 staffers lose their jobs due to FDA layoffs, venture capital (VC) term sheets shrink, and AI drug-discovery startups raise $600 million rounds? Executive recruiter William Holodnak (ex-Fidelity, global biotech headhunter) breaks down 2025’s wild hiring market—and how founders can still build A-teams. In this episode you’ll learn: - Why the April-1 FDA layoffs could delay approvals—and open new career doors for ex-regulators. - The three traits VCs deman...
Why Most Healthcare Brands Fail (And How to Fix It) In this episode, Holley Miller, Founder and President of Grey Matter Marketing, reveals why most medtech and life sciences companies fail to connect with their audience—and how to fix that with brand clarity and strategic storytelling. You’ll learn how marketing in regulated industries is evolving, why flashy tactics often fall flat, and how brand equity is built through consistency, credibility, and emotional connection. Holley also share...
Solving the “Undruggable” Disease Problem with Goldilocks Molecules In this episode, Christian Schafmeister, Founder and President of Third Law Molecular, reveals a new class of therapeutics designed to target what most consider “undruggable” diseases—conditions like Alzheimer’s, certain cancers, and rare genetic disorders. Christian explains the science behind spiroligomers—modular, mid-sized molecules that act like molecular LEGOs, offering the perfect balance between small molecules and ...
Why Startups Fail (Hint: It’s Not the Innovation) In this episode, Carlo Odicino, CEO and Founder at One TEAM Partners, shares the real reasons why most early-stage life sciences companies struggle to survive—and it has nothing to do with bad science. Learn the hidden pitfalls of scaling too fast, confusing innovation with execution, and chasing too many priorities at once. Carlo offers practical strategies for building focus, setting boundaries, and creating a people-first culture that act...
The Hidden Math Behind Drug Pricing: Why Patients Pay More Than They Should In this episode, Michael Grosberg, VP of Product Management at Model N, breaks down the complex drug pricing ecosystem—revealing how rebates, PBMs, and outdated pricing models shape what patients actually pay. You’ll learn how Pharmacy Benefit Managers (PBMs) really operate, why list prices are misleading, and how pricing negotiations impact patient access. Michael also unpacks the mechanics behind patient assistanc...
Early Commercialization Strategies That Actually Work (Especially for Startups!) In this episode, John Harlow, Chief Commercial Officer at Melinta Therapeutics, shares real-world strategies for how lean pharma startups can win the commercialization game—without Big Pharma budgets. Discover how small companies can pivot fast, creatively optimize distribution, and make strategic decisions without endless red tape. John breaks down the critical mindset shift from R&D to commercial readiness...
Healthcare AI adoption is transforming the way we address risk, confidentiality, and patient care. In this episode, RJ Kedziora, co-founder of Estenda Solutions talks about the practical steps to safely integrate AI in clinical workflows. Learn how to manage data privacy, mitigate algorithmic bias, and keep a human in the loop to prevent misdiagnoses. Discover real-world strategies for using AI ethically, from ambient listening to second-opinion checks, and why it’s irresponsible not to har...
Drug serialization is at the heart of modern pharmaceutical supply chain security. In this episode Michael Rowe, Senior Director of DSCSA and Serialization Services at TwoLabs, talks about the critical role of drug serialization and DSCSA compliance in safeguarding the pharmaceutical supply chain. Michael explains how unique serial numbers, standardized data, and digital traceability are revolutionizing how drugs are tracked from manufacturer to pharmacy. Discover real-world challen...
Equitable healthcare is the key to bridging health gaps and creating better patient outcomes. In this episode, Amy West, Principal, Advisory Services at HitLab, share her insights on how technology, digital health, and data can reshape access to care—especially for underserved communities. Learn how addressing social determinants, using remote patient monitoring, and integrating wearables can empower patients and reduce disparities. From real-world examples to actionable insights, Amy sha...
Have you ever wondered if AI could help doctors find cancer faster and more accurately? In this episode, we explore OmniScreen, an AI-powered biomarker tool that is revolutionizing cancer diagnostics. Joe Oakley, a pathologist and expert in digital pathology, explains how OmniScreen was trained on 3 million digital slides to detect cancer biomarkers with higher precision and speed. He shares how AI is reducing testing time, preserving tissue samples, and improving early cancer detection. We a...
Have you ever wondered why marketing in the life sciences industry is so different from traditional marketing? In this episode, we dive deep into the power of science marketing, the impact of brand storytelling, and how companies can successfully position their products in a competitive market. From publishing content to collaboration with industry, we'll show you how to harness the power of science marketing for success. Why do some breakthrough innovations never reach their full potential,...
Have you ever wondered why so many new drugs fail even after years of research and billions in investment? In this episode, we dive deep into the challenges of drug commercialization, the role of AI in pharma, and the biggest mistakes companies make before going to market. Our guest, Dan Cummings, is a leading expert in go-to-market strategy, having worked with top health tech, medtech, and biotech startups. He shares insider insights on why even successful clinical trials don’t guarantee a p...
Have you ever wondered why so many clinical trials fail before reaching the market? In this episode, we dive deep into the hidden challenges of clinical trials with Rob Freishtat, President and Co-Founder of Uncommon Cures and a professor at George Washington University School of Medicine and Health Sciences. Rob shares insider knowledge on why over 55% of clinical trials fail, the high costs of drug development, and how misaligned priorities between researchers, regulators, and sponsors can ...
Welcome to episode 045 of Life Sciences 360. On this episode, Nagesh Nama and his team at XLM talk on why Gen.AI is essential in the software test world and share examples of its use in various industries, particularly in life sciences and manufacturing. They address the challenges faced by companies in adopting AI and provide solutions for integrating AI into existing systems. Harsh and his guests discuss how AI can improve productivity, enhance quality assurance processes, and enable pr...
Dr. Arnon Chait, CEO of Cleveland Diagnostics, discusses his transition from NASA to the healthcare innovation space and the development of cancer diagnostics. Dr. Chait emphasizes the importance of using diagnostic advancements to strike a balance between over-screening and under-treating, particularly in the workup of cancer after failed screenings. He discusses the development of their innovative prostate cancer diagnostic test. In Episode 044 of Life Sciences 360, Harsh and Arnon...
With the market estimated to reach $11.5 billion by 2028. Clean Rooms on Demand is providing flexible and cost-effective solutions for biotech and pharma companies. The benefits of using clean rooms on demand include avoiding the high capital outlay and ongoing operational expenses of building and maintaining their own facilities, as well as the flexibility to scale up or down as needed. Join me in Episode 43 of Life Sciences 360, with Sarah Stevens, the President of Azzur Labs and Azzur ...
How can behavioral science optimize pharmaceutical practices? Episode 042: Will Hind, CEO of Alpharmaxim Healthcare Communications, discusses the challenges and opportunities in integrating behavioral science with pharma strategies. Find out how this can lead to better patient outcomes and more tailored healthcare solutions. ----- Links: *Will Hind LinkedIn *Will Hind X *Alpharmaxim *Harsh Thakkar LinkedIn *Would you rather watch the episode? Click here! 📝 Leave us a review! 🔔 Subsc...
Episode 041: J.D. Mowery, President and CEO of KBI Biopharma, discusses his career journey and the role of CDMOs in the biotech and pharma industry. He emphasizes the importance of relationships, risk-taking, and continuous learning in his career success. J.D. highlights the unique combination of expertise required to work in both biotech and CDMO companies. He explains the challenges faced by biotech and pharma companies that have led to the rise of CDMOs. Harsh asks J.D. to share the ke...
Are you interested in how the latest flow technology is transforming biopharmaceutical manufacturing? Join us for Episode 40 of the Life Sciences 360 podcast, where Harsh Thakkar (@harshvthakkar), CEO of Qualtivate sits down with Bethany Silva (@bethany-silva), Life Sciences Industry Manager at Endress+Hauser. They delve deep into the world of flow measurement, focusing on the cutting-edge single-use flow meters based on the Coriolis principle and how this technology is crucial for the de...